Sabine Blum

Publications | Phd and Masters theses

Advanced search is available through Serval

Publications can be managed by accessing Serval via MyUnil


100 publications

2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2003 | 2000 |
2024
Differentiation syndrome in acute promyelocytic leukemia: A leopard cannot change its spots.
Schiavini G., Blum S., Tsilimidos G., 2024/12. International journal of laboratory hematology, 46 (6) pp. 983-984. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_17D6F94EA24E]
 
Incidence and outcome of central nervous system relapse after hematopoietic stem cell transplantation in patients suffering from acute myeloid leukemia and acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Blum S., Chalandon Y., Labopin M., Finke J., Gedde-Dahl T., Othman T.B., Cornelissen J.J., Jindra P., Labussière-Wallet H., Collin M. et al., 2024/07/01. Haematologica, 109 (7) pp. 2346-2350. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_DD7AEE6D7D42]
 
Anémie aplasique [Aplastic anemia]
Dewarrat N., Costanza M., Royer-Chardon C., Zermatten M.G., De Leval L., Naveiras O., Blum S., 2024/06/26. Revue medicale suisse, 20 (880) pp. 1271-1275. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_CEA94396449F]
 
Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia.
Chalandon Y., Rousselot P., Chevret S., Cayuela J.M., Kim R., Huguet F., Chevallier P., Graux C., Thiebaut-Bertrand A., Chantepie S. et al., 2024/06/06. Blood, 143 (23) pp. 2363-2372. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_89C66CC22232]
 
Philadelphia chromosome-positive B cell acute lymphoblastic phase arising 24 years after treatment-free remission for chronic myeloid leukemia with identical BCR-ABL fusion transcript.
Dereme J., Voruz S., Solly F., Schoumans J., Blum S., 2024/03. Annals of hematology, 103 (3) pp. 1027-1029. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_481C8EC02EB3]
The new WHO 2022 and ICC proposals for the classification of myelodysplastic neoplasms. Validation based on the Düsseldorf MDS Registry and proposals for a merged classification.
Nachtkamp K., Strupp C., Vukelja M., Kasprzak A., Haase D., Ganster C., Hildebrandt B., Betz B., Giagounidis A., Aul C. et al., 2024/02. Leukemia, 38 (2) pp. 442-445. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9A7894B92AD3]
2023
Refined cytogenetic IPSS-R evaluation by the use of SNP array in a cohort of 290 MDS patients.
Scarpelli I., Stalder V.B., Tsilimidos G., Rapakko K., Costanza M., Blum S., Schoumans J., 2023/12. Genes, chromosomes & cancer, 62 (12) pp. 721-731. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_C61747071E47]
 
Single-center, observational study of AML/MDS-EB with IDH1/2 mutations: genetic profile, immunophenotypes, mutational kinetics and outcomes.
Papadopoulou V., Schoumans J., Basset V., Solly F., Pasquier J., Blum S., Spertini O., 2023/12. Hematology, 28 (1) p. 2180704. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E1AEFA186EFE]
 
Genetic alterations and MRD refine risk assessment for KMT2A-rearranged B-cell precursor ALL in adults: a GRAALL study.
Kim R., Bergugnat H., Pastoret C., Pasquier F., Raffoux E., Larcher L., Passet M., Grardel N., Delabesse E., Kubetzko S. et al., 2023/11/23. Blood, 142 (21) pp. 1806-1817. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C76A626B4003]
 
Effets secondaires des inhibiteurs de tyrosine kinase dans la leucémie myéloïde chronique [Recognizing and managing side effects of tyrosine kinase inhibitors in chronic myeloid leukemia]
Dereme J., Ségot A., Friedrich N., Tsilimidos G., Blum S., 2023/11/15. Revue medicale suisse, 19 (850) pp. 2175-2181. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_8CD75E04E5AE]
 
Exploring the Heterogeneity of Response to Blinatumomab in High-Risk Philadelphia-Negative B-Cell Precursor Acute Lymphoblastic Leukemia: An Analysis from the QUEST Sub-Study of the Graall-2014/B Trial
Boissel Nicolas, Huguet Francoise, Leguay Thibaut, Hunault Mathilde, KIM Rathana, Hicheri Yosr, Passet Marie, Chevallier Patrice, Balsat Marie, Maury Sebastien et al., 2023/11/02., 65th ASH Annual Meeting December 9-12, 2023 pp. 4349-4349 dans Blood.
[DOI][WoS][serval:BIB_A4AA9849D86B]
 
Comparative analysis of automated cell counts in oncological patients: Reliable results of point of care blood impedance measurements and pitfalls in myelodysplastic neoplasias and acute myeloid leukemias.
Blum S., Costanza M., Coutaz C., Naveiras O., Spertini O., Tsilimidos G., Alberio L., 2023/10. International journal of laboratory hematology, 45 (5) pp. 818-821. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_BF3096D4C446]
 
Comment on: JAK2 V617F-mutated polycythemia vera developing in a patient with a 20-year-long chronic myeloid leukemia at the time of first molecular response.
Tsilimidos G., Blum S., 2023/09. Annals of hematology, 102 (9) pp. 2619-2620. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_89A63BC77588]
 
Développements récents en hématologie, Partie 2
Duchosal Michel A., Alberio Lorenzo, Angelillo-Scherrer Anne, Arber Caroline, Balabanov Stefan, Blum Sabine, Bttcher Steffen, Buser Andreas, Cairoli Anne, Chalandon Yves et al., 2023/08/23. Forum Médical Suisse ‒ Swiss Medical Forum.
[DOI][serval:BIB_E9D38C229944]
 
Développements récents en hématologie, Teil 1
Duchosal Michel A., Alberio Lorenzo, Angelillo-Scherrer Anne, Arber Caroline, Balabanov Stefan, Blum Sabine, Bttcher Steffen, Buser Andreas, Cairoli Anne, Chalandon Yves et al., 2023/08/16. Forum Médical Suisse ‒ Swiss Medical Forum.
[DOI][serval:BIB_BEEE6D0FAED7]
 
Oedème palpébral 24 heures après le premier vaccin contre le COVID-19
Dao Mai-Chi Diane, Opota Onya, Blum Sabine, 2023/08/16. Forum Médical Suisse ‒ Swiss Medical Forum.
[DOI][serval:BIB_03E4EDAE9BE2]
The Absolute Monocyte Count at Diagnosis Affects Prognosis in Myelodysplastic Syndromes Independently of the IPSS-R Risk Score.
Silzle T., Blum S., Kasprzak A., Nachtkamp K., Rudelius M., Hildebrandt B., Götze K.S., Gattermann N., Lauseker M., Germing U., 2023/07/11. Cancers, 15 (14) p. 3572. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4EBDEBD46B00]
Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine.
Hilberink J.R., van Zeventer I.A., Chitu D.A., Pabst T., Klein S.K., Stussi G., Griskevicius L., Valk PJM, Cloos J., van de Loosdrecht A.A. et al., 2023/06/19. Blood cancer journal, 13 (1) p. 93. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4F3DD7E2D528]
 
Role of Bcl-2 inhibition in myelodysplastic syndromes.
Blum S., Tsilimidos G., Bresser H., Lübbert M., 2023/04/15. International journal of cancer, 152 (8) pp. 1526-1535. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_BBA81966D4CC]
MarrowQuant 2.0: A Digital Pathology Workflow Assisting Bone Marrow Evaluation in Experimental and Clinical Hematology.
Sarkis R., Burri O., Royer-Chardon C., Schyrr F., Blum S., Costanza M., Cherix S., Piazzon N., Barcena C., Bisig B. et al., 2023/04. Modern pathology, 36 (4) p. 100088. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_352A9711DE44]
Description of an Institutional Cohort of Myeloid Neoplasms Carrying ETV6-Locus Deletions or ETV6 Rearrangements.
Papadopoulou V., Schoumans J., Scarpelli I., Blum S., 2023. Acta haematologica, 146 (5) pp. 401-407. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4670AF426CC7]
 
Long-standing thrombocytosis often precedes thromboembolic complications heralding the diagnosis of essential thrombocythemia.
Stalder G., Da Silva W.R., Segot A., Blum S., Grandoni F., Alberio L., 2023/01. European journal of internal medicine, 107 pp. 110-112. Peer-reviewed.
[DOI][Pmid][serval:BIB_08DE4C04AF7F]
2022
 
HHV8-negative primary effusion-based large B-cell lymphoma in a patient with chronic myeloid leukemia, BCR::ABL1-positive under dasatinib treatment: Report of a new case and literature review.
Christe L., Veloza L., Gros L., Bisig B., Blum S., Hewer E., de Leval L., 2022/12. Diagnostic cytopathology, 50 (12) pp. E351-E356. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_BFCAD836C568]
 
Altered platelet functions during treatment with apremilast for psoriatic arthritis: A case report.
Tsilimidos G., Blum S., Aliotta A., Dumusc A., Alberio L., 2022/09. Current research in translational medicine, 70 (4) p. 103358. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2BE6A07E6049]
 
Hepatitis B reactivation during ruxolitinib treatment.
Sjoblom M., Chtioui H., Fraga M., Stalder G., Grandoni F., Blum S., 2022/09. Annals of hematology, 101 (9) pp. 2081-2086. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_97208521780E]
Syndrome des télomères courts chez l’adulte : une entité rare qu’il faut savoir évoquer [Short telomere syndrome in adults: a rare entity that should be evoked]
Coukos A., Daccord C., Lazor R., Blum S., Naveiras O., Unger S., Vionnet J., Gaide O., Koutsokera A., Moschouri E. et al., 2022/08/31. Revue medicale suisse, 18 (793) pp. 1606-1613. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_610156412D48]
Neisseria meningitidis in peripheral blood smear.
Dewarrat N., Bovey F., Kaiser J., Blum S., 2022/06. International journal of laboratory hematology, 44 (3) pp. 444-445. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_68ED02B992DE]
Evolving Treatment Landscape of AML
Blum Sabine, Bacher Ulrike, Pabst Thomas, 2022/03/01. healthbook TIMES Onco Hema. Peer-reviewed.
[URN][serval:BIB_CB91AEEE60C6]
Venetoclax combined with FLAG-based chemotherapy induces an early and deep response in mixed-phenotype-acute leukemia.
Ségot A., Stalder G., de Leval L., Solly F., Schoumans J., Basset V., Blum S., Spertini O., 2022/03/01. American journal of hematology, 97 (3) pp. E91-E93. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_92714D3B5868]
Isolated skin infiltration by a blastic plasmacytoid dendritic cell neoplasm.
Stalder G., Milowich D., Blum S., Schoumans J., Bisig B., Spertini O., 2022/02. EJHaem, 3 (1) pp. 259-260. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_EC0E8BADE124]
2021
Daratumumab and venetoclax in combination with chemotherapy provide sustained molecular remission in relapsed/refractory CD19, CD20, and CD22 negative acute B lymphoblastic leukemia with KMT2A-AFF1 transcript.
Voruz S., Blum S., de Leval L., Schoumans J., Solly F., Spertini O., 2021/12/20. Biomarker research, 9 (1) p. 92. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_3AC8AE13FD49]
 
Hypoplastisches myelodysplastisches Syndrom
Grandoni Francesco, Dewarrat Natacha, Blum Sabine, 2021/10/20. InFo Hämatol Onkol , 24 (10) pp. 22-25.
[DOI][serval:BIB_AA581B79E784]
Postpartum hemorrhage risk is driven by changes in blood composition through pregnancy.
Robinson M.R., Patxot M., Stojanov M., Blum S., Baud D., 2021/09/28. Scientific reports, 11 (1) p. 19238. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_BA8FC21210D4]
EHA Endorsement of the European Guidelines for Myelodysplastic Syndromes, MDS-RIGHT.
Blum S., Malcovati L., 2021/09. HemaSphere, 5 (9) pp. e631. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E8496C34141B]
Bone marrow adiposity and the hematopoietic niche: A historical perspective of reciprocity, heterogeneity, and lineage commitment.
Tratwal J., Rojas-Sutterlin S., Bataclan C., Blum S., Naveiras O., 2021/07. Best practice & research. Clinical endocrinology & metabolism, 35 (4) p. 101564. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_5C7C2C3C9CA3]
 
Décompensation cardiaque, arthralgies et prurit généralisé
Tsilimidos Gerasimos, Grandoni Francesco, Blum Sabine, Alberio Lorenzo, Rotman Samuel, Gavillet Mathilde, 2021/03/30. Forum Médical Suisse ‒ Swiss Medical Forum.
[DOI][serval:BIB_4E930E7D1E61]
 
Acquired haemophilia A in the postpartum and risk of relapse in subsequent pregnancies: A systematic literature review.
Dewarrat N., Gavillet M., Angelillo-Scherrer A., Naveiras O., Grandoni F., Tsakiris D.A., Alberio L., Blum S., 2021/03. Haemophilia, 27 (2) pp. 199-210. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C7857B4FC41A]
Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS.
Kuendgen A., Nomdedeu M., Tuechler H., Garcia-Manero G., Komrokji R.S., Sekeres M.A., Della Porta M.G., Cazzola M., DeZern A.E., Roboz G.J. et al., 2021/03. Leukemia, 35 (3) pp. 835-849. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_389289378560]
 
Characterization of myelodysplastic syndromes progressing to acute lymphoblastic leukemia.
Martins F., Kruszewski M., Scarpelli I., Schoumans J., Spertini O., Lübbert M., Blum S., 2021/01. Annals of hematology, 100 (1) pp. 63-78. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_387FEDC64B22]
2020
 
Heavy metal.
Dewarrat N., Blum S., 2020/10/22. Blood, 136 (17) p. 1993. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_3195FFDA4694]
 
Management of erroneous subcutaneous injection of vincristine.
de Goycoechea D., Dewarrat N., Rothuizen L.E., Matter M., Nagy M., Locher G., Spertini O., Blum S., 2020/10. Leukemia & lymphoma, 61 (10) pp. 2530-2532. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_641B75CE53D5]
Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS.
Huls G., Chitu D.A., Pabst T., Klein S.K., Stussi G., Griskevicius L., Valk PJM, Cloos J., van de Loosdrecht A.A., Breems D. et al., 2020/09/22. Blood advances, 4 (18) pp. 4267-4277. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_BA95A00DDE07]
 
Progressive multifocal leukoencephalopathy responsive to withdrawal of imatinib in a patient with FIP1L1-PDGFRA positive myeloid neoplasm.
Blum S., Dunet V., Comoli P., Tirefort Y., Chalandon Y., Opota O., Comte D., Spertini O., Livio F., Brouland J.P. et al., 2020/09. Leukemia & lymphoma, 61 (9) pp. 2226-2229. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_13EB95E6B61C]
 
Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial.
Benz R., Arn K., Andres M., Pabst T., Baumann M., Novak U., Hitz F., Hess U., Zenhaeusern R., Chalandon Y. et al., 2020/08/11. Blood advances, 4 (15) pp. 3699-3707. Peer-reviewed.
[DOI][Pmid][serval:BIB_691BFBDC1C74]
COVID-19, une approche polyphonique.
Blum S., Gavillet M., 2020/04/29. Revue medicale suisse, 16 (N° 691-2) p. 809. Peer-reviewed.
[URN][Pmid][serval:BIB_E0FBCBBAA7A4]
 
L’hématologie au temps du COVID-19 [Hematology in the time of COVID-19]
Gavillet M., Rufer N., Grandoni F., Carr Klappert J., Zermatten M.G., Cairoli A., Canellini G., Alberio L., Duchosal M.A., Spertini O. et al., 2020/04/29. Revue medicale suisse, 16 (N° 691-2) pp. 823-826. Peer-reviewed.
[Pmid][serval:BIB_C2EE66B2AA4D]
Acute leukemia in the time of COVID-19.
Gavillet M., Carr Klappert J., Spertini O., Blum S., 2020/03/26. Leukemia research, 92 p. 106353. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_82B8BF1043A6]
 
Risk of B-cell lymphoma in MPN patients treated with JAK1/2 inhibitors: Contradictory results?
Costanza M., Spertini O., Blum S., 2020/03. Leukemia research, 90 p. 106313. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_10DE436CD9F2]
2019
Successful desensitization to pomalidomide in a patient with POEMS syndrome with delayed-type hypersensitivity to immunomodulatory imid drugs.
Grandoni F., Stalder G., Borgeat Kaeser A., Ribi C., Cairoli A., Blum S., 2019/12. Leukemia & lymphoma, 60 (12) pp. 3087-3089. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A815C7BA260F]
 
Fungal spore contamination mimicking parasitic infection.
Blum S., Cairoli A., 2019/09/05. Blood, 134 (10) p. 841. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F8758958FE7F]
Lymphopenia at diagnosis is highly prevalent in myelodysplastic syndromes and has an independent negative prognostic value in IPSS-R-low-risk patients.
Silzle T., Blum S., Schuler E., Kaivers J., Rudelius M., Hildebrandt B., Gattermann N., Haas R., Germing U., 2019/08/09. Blood cancer journal, 9 (8) p. 63. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E6110C1C36FA]
 
Contamination.
Bloch J., Blum S., 2019/04/04. Blood, 133 (14) p. 1612. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2E5D72CD5D2B]
 
Ten-year single-centre experience in fertility preservation of 459 patients suffering from acute leukaemia.
Noetzli J., Voruz S., Wunder D., Primi M.P., Spertini O., Blum S., 2019/03. British journal of haematology, 184 (6) pp. 969-973. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_9AD1D6CC6F77]
2018
 
Long-term outcome of high risk patients with myelodysplastic syndromes or secondary acute myeloid leukemia receiving intensive chemotherapy.
Schuler E., Zadrozny N., Blum S., Schroeder T., Strupp C., Hildebrandt B., Kündgen A., Gattermann N., Aul C., Kondakci M. et al., 2018/12. Annals of hematology, 97 (12) pp. 2325-2332. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D7A4803DB8A5]
 
Over 20 years of treatment-free remission after interferon-alpha monotherapy for chronic myeloid leukemia.
Bloch J., Spertini O., Stucki A., Solly F., Blum S., 2018/10. Leukemia research, 73 pp. 103-104. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_DA8C4FDC5E5F]
 
Pseudo Chediak-Higashi anomaly in blasts from acute lymphoblastic leukemia.
Gavillet M., Spertini O., Blum S., 2018/07. Leukemia research, 70 pp. 87-90. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D1FB6B3E560D]
 
Influence of Haemodialysis on Imatinib Plasma Levels in a Case of Philadelphia Positive Acute Lymphoblastic Leukemia
de Goycoechea Diego, Schleyer Eberhard, Naveiras Olaia, Gattermann Norbert, Blum Sabine, 2018/05/25. Annals of Clinical Case Reports.
[serval:BIB_18F02F14B71C]
Comment on "MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma".
Voruz S., Martins F., Cairoli A., Naveiras O., Homicsko K., Missiaglia E., de Leval L., Bisig B., Michielin O., Blum S., 2018/03. Haematologica, 103 (3) pp. e130. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0845E1BF99E5]
Response to MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma.
Voruz S., Cairoli A., Naveiras O., de Leval L., Missiaglia E., Homicsko K., Michielin O., Blum S., 2018/01. Haematologica, 103 (1) pp. e39-e41. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_12A8F7D8B626]
2017
 
Immunotherapy in adult acute leukemia.
Blum S., Martins F., Lübbert M., 2017/09. Leukemia research, 60 pp. 63-73. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_EC3D9761AFA8]
 
Innovative strategies for adverse karyotype acute myeloid leukemia.
Blum S., Greve G., Lübbert M., 2017/03. Current opinion in hematology, 24 (2) pp. 89-98. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CD319BE75546]
 
Trends of classification, incidence, mortality, and survival of MDS patients in Switzerland between 2001 and 2012.
Bonadies N., Feller A., Rovo A., Ruefer A., Blum S., Gerber B., Stuessi G., Benz R., Cantoni N., Holbro A. et al., 2017/02. Cancer epidemiology, 46 pp. 85-92. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4E30164F031A]
2016
Une leucocytose avec bicytopénie
Jankovic Jeremy, Blum Sabine, 2016/12/06. Forum Médical Suisse ‒ Swiss Medical Forum, 16 (4950).
[URN][DOI][serval:BIB_C68E193B9713]
Temps de thromboplastine partiel activé allongé, que faire?
Aslan Nurullah, Alberio Lorenzo, Blum Sabine, 2016/10/11. Forum Médical Suisse ‒ Swiss Medical Forum, 16 (41).
[URN][DOI][serval:BIB_DCFE859A3A76]
Ruxolitinib in the treatment of polycythemia vera: patient selection and special considerations.
Blum S., Martins F., Alberio L., 2016. Journal of Blood Medicine, 7 pp. 205-215. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_AC50BBB0C2BA]
 
Thromboembolie und Antikoagulation bei Tumorpatienten []
Grandoni F., Kaiser J., Blum S., Alberio L., 2016. Therapeutische Umschau. Revue therapeutique, 73 (10) pp. 595-604. Peer-reviewed.
[DOI][Pmid][serval:BIB_115AB0DBE476]
2015
 
“Atypical” macrophages.
Bloch J., Blum S., 2015/04/02. Blood, 125 (14) p. 2305. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_70436B2A16F4]
 
Antiplatelet Therapy and Anticoagulation
Chassot P.G., Barelli S., Blum S., Angelillo-Scherrer A., Marcucci C., 2015. pp. 109-130 dans Perioperative hemostasis chap. 8, Springer.
[DOI][serval:BIB_3447E1DC77BF]
 
Cellularity, characteristics of hematopoietic parameters and prognosis in myelodysplastic syndromes.
Schemenau J., Baldus S., Anlauf M., Reinecke P., Braunstein S., Blum S., Nachtkamp K., Neukirchen J., Strup C., Aul C. et al., 2015. European Journal of Haematology, 95 (3) pp. 181-189. Peer-reviewed.
[DOI][Pmid][serval:BIB_433CD5C9496F]
2014
 
Azacytidine for acute myeloid leukemia in elderly or frail patients: a phase II trial (SAKK 30/07).
Passweg J.R., Pabst T., Blum S., Bargetzi M., Li Q., Heim D., Stussi G., Gregor M., Leoncini L., Meyer-Monard S. et al., 2014. Leukemia and Lymphoma, 55 (1) pp. 87-91.
[DOI][WoS][Pmid][serval:BIB_EFBD423076BB]
 
Validation of the revised international prognostic scoring system (IPSS-R) in patients with myelodysplastic syndrome: a multicenter study.
Neukirchen J., Lauseker M., Blum S., Giagounidis A., Lübbert M., Martino S., Siragusa S., Schlenk R.F., Platzbecker U., Hofmann W.K. et al., 2014. Leukemia Research, 38 (1) pp. 57-64. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2CC848AADF0C]
2012
Transfusion independence and survival in patients with acute myeloid leukemia treated with 5-azacytidine.
Gavillet M., Noetzli J., Blum S., Duchosal M.A., Spertini O., Lambert J.F., 2012/12. Haematologica, 97 (12) pp. 1929-1931. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B9132A398C21]
 
Block of red blood cell maturation in acute erythroid leukemia.
Blum S., Angelillo-Scherrer A., 2012. Blood, 120 (10) p. 1974.
[WoS][Pmid][serval:BIB_2FFF00CCEAD9]
 
Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study.
Germing U., Lauseker M., Hildebrandt B., Symeonidis A., Cermak J., Fenaux P., Kelaidi C., Pfeilstöcker M., Nösslinger T., Sekeres M. et al., 2012. Leukemia, 26 (6) pp. 1286-1292.
[DOI][WoS][Pmid][serval:BIB_3715D1EBA05D]
2011
Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q.
Mallo M., Cervera J., Schanz J., Such E., García-Manero G., Luño E., Steidl C., Espinet B., Vallespí T., Germing U. et al., 2011. Leukemia, 25 (1) pp. 110-120. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_BD04315DCC0E]
2010
 
Evaluation of the prognostic significance of eosinophilia and basophilia in a larger cohort of patients with myelodysplastic syndromes.
Wimazal F., Germing U., Kundi M., Noesslinger T., Blum S., Geissler P., Baumgartner C., Pfeilstoecker M., Valent P., Sperr W.R., 2010/05/15. Cancer, 116 (10) pp. 2372-2381. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_423167CED7F3]
 
5-Azacytidine to Treat Acute Myeloid Leukemia In Elderly or Frail Patients: A Phase II Study (SAKK 30/07).
Passweg J.R., Pabst T., Blum S., Bargetzi M., Sun H., Heim D., Stussi G., Gregor M., Leoncini L., Meyer-Monard S. et al., 2010. p. 900 dans 52nd Annual Meeting of the American Society of Hematology (ASH), Blood.
[WoS][serval:BIB_85F59D630C8B]
 
Recommendations for the diagnosis and treatment of myelodysplastic syndromes in adult patients in Switzerland
Passweg J.R., Duchosal M.A., Hess U., Blum S., Freiburghaus A.U., Bargetzi M., Binder D., Dirnhofer St., Friess D., Goede J.S. et al., 2010. Swiss Medical Forum = Forum Médical Suisse, 10 (15) pp. 259-265.
[serval:BIB_D1F2EAA2AB70]
Treatment of 5q-syndrome with lenalidomide in an HIV-positive patient under cART.
Blum Sabine, Cavassini Matthias, Lambert Jean-Francois, Fayet Aurelie, Schapira Marc, Jotterand Martine, 2010. Annals of Hematology, 89 (4) pp. 425-426.
[URN][DOI][WoS][Pmid][serval:BIB_6513BEF5AFEB]
2009
Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromes.
Neukirchen J., Blum S., Kuendgen A., Strupp C., Aivado M., Haas R., Aul C., Gattermann N., Germing U., 2009/11. European journal of haematology, 83 (5) pp. 477-482. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_156D26735046]
 
Repeated responses of an elderly patient with high-risk myelodysplastic syndrome to sequential therapy with tipifarnib, 5-azacitidine, and decitabine.
Möller I., Blum S., Gattermann N., Haas R., Habersang K., Germing U., Kuendgen A., 2009/11. Annals of hematology, 88 (11) pp. 1141-1144. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_AC01ECE5247F]
 
Die Rationale für Knochenmarkuntersuchungen bei Patienten mit entzündlich-rheumatischen Erkrankungen [Rationale for bone marrow examination in patients with inflammatory rheumatic diseases]
Richter J.G., Gossen P., Germing U., Blum S., Hildebrandt B., Braunstein S., Huscher D., Schneider M., 2009. Wiener klinische Wochenschrift, 121 (21-22) pp. 690-699. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_126D45BB2E01]
Imatinib in breast milk
Kronenberger R., Schleyer E., Bornhaeuser M., Ehninger G., Gattermann N., Blum S., 2009. Annals Of Hematology, 88 (12) pp. 1265-1266.
[URN][DOI][WoS][serval:BIB_DC149A690971]
2008
 
Steroid-responsive cauda equina syndrome associated with GVHD after allogeneic hematopoietic stem cell transplantation.
Terrettaz M., Verholen F., Passweg J., Knipp S., Burkhard P.R., Chalandon Y., 2008/02. Bone marrow transplantation, 41 (3) pp. 315-316. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_5D6F85E123C3]
2007
Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement
Knipp S., Gattermann N., Schapira M., Kaferstein H., Germing U., 2007/11. Leukemia Research, 31 (11) pp. 1585-7.
[URN][DOI][WoS][Pmid][serval:BIB_EDE42B00030B]
Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes.
Malcovati L., Germing U., Kuendgen A., Della Porta M.G., Pascutto C., Invernizzi R., Giagounidis A., Hildebrandt B., Bernasconi P., Knipp S. et al., 2007/08/10. Journal of clinical oncology, 25 (23) pp. 3503-3510. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_347B8C63AE64]
 
Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes.
Knipp S., Hildebrand B., Kündgen A., Giagounidis A., Kobbe G., Haas R., Aul C., Gattermann N., Germing U., 2007/07/15. Cancer, 110 (2) pp. 345-352. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_95CEDBFCDFEA]
 
Chronic myelomonocytic leukemia in the light of the WHO proposals.
Germing U., Strupp C., Knipp S., Kuendgen A., Giagounidis A., Hildebrandt B., Aul C., Haas R., Gattermann N., Bennett J.M., 2007/07. Haematologica, 92 (7) pp. 974-977. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4001811B48FA]
 
A pilot study of bendamustine in elderly patients with high-risk MDS and AML.
Strupp C., Knipp S., Hartmann J., Gattermann N., Haas R., Germing U., 2007/06. Leukemia & lymphoma, 48 (6) pp. 1161-1166. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4B86DB385FF3]
 
Presence of peripheral blasts in refractory anemia and refractory cytopenia with multilineage dysplasia predicts an unfavourable outcome
Knipp S., Strupp C., Gattermann N., Hildebrandt B., Schapira M., Giagounidis A., Aul C., Haas R., Germing U., 2007/04. Leukemia Research.
[DOI][WoS][Pmid][serval:BIB_DCFEC23CBBAF]
2006
 
Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes.
Germing U., Strupp C., Kuendgen A., Isa S., Knipp S., Hildebrandt B., Giagounidis A., Aul C., Gattermann N., Haas R., 2006/12. Haematologica, 91 (12) pp. 1596-1604. Peer-reviewed.
[WoS][Pmid][serval:BIB_E25C65E11AC9]
 
Exisulind induces apoptosis in advanced myelodysplastic syndrome (MDS) and acute myeloid leukaemia/MDS.
Czibere A., Prall W.C., Zerbini L.F., Jäger M., Kobbe G., Knipp S., Libermann T.A., Haas R., Aivado M., 2006/11. British journal of haematology, 135 (3) pp. 355-357. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_753ADAC383A2]
 
Secondary myelodysplastic syndrome following long-term treatment with azathioprine in patients with multiple sclerosis.
Putzki N., Knipp S., Ramczykowski T., Vago S., Germing U., Diener H.C., Limmroth V., 2006/06. Multiple sclerosis, 12 (3) pp. 363-366. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0F4271488966]
 
The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia.
Kuendgen A., Schmid M., Schlenk R., Knipp S., Hildebrandt B., Steidl C., Germing U., Haas R., Dohner H., Gattermann N., 2006/01/01. Cancer, 106 (1) pp. 112-119. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_00E198422F61]
2005
 
Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia.
Kuendgen A., Knipp S., Fox F., Strupp C., Hildebrandt B., Steidl C., Germing U., Haas R., Gattermann N., 2005/12. Annals of hematology, 84 Suppl 1 pp. 61-66. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_87D4BAE36763]
Difference in clinical features between Japanese and German patients with refractory anemia in myelodysplastic syndromes.
Matsuda A., Germing U., Jinnai I., Misumi M., Kuendgen A., Knipp S., Aivado M., Iwanaga M., Miyazaki Y., Tsushima H. et al., 2005/10/15. Blood, 106 (8) pp. 2633-2640. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_BD8089DF5D95]
 
Secondary myelodysplastic syndromes following treatment with azathioprine are associated with aberrations of chromosome 7.
Knipp S., Hildebrandt B., Richter J., Haas R., Germing U., Gattermann N., 2005/05. Haematologica, 90 (5) pp. 691-693. Peer-reviewed.
[WoS][Pmid][serval:BIB_AC57CA72EBF5]
2003
 
Ex vivo apoptosis, CD95 and CD28 expression in T cells of children with juvenile idiopathic arthritis.
Knipp S., Feyen O., Ndagijimana J., Niehues T., 2003/05. Rheumatology international, 23 (3) pp. 112-115. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_85913AF561CE]
2000
 
Treatment-resistant expansion of CD8+CD28-cells in pediatric HIV infection.
Niehues T., Horneff G., Knipp S., Adams O., Wahn V., 2000/03. Pediatric research, 47 (3) pp. 418-421. Peer-reviewed.
[WoS][Pmid][serval:BIB_12302055C750]
 
Relapsing polychondritis in childhood--case report and short review.
Knipp S., Bier H., Horneff G., Specker C., Schuster A., Schroten H., Lenard H.G., Niehues T., 2000. Rheumatology international, 19 (6) pp. 231-234. Peer-reviewed.
[WoS][Pmid][serval:BIB_54CDB15AE66B]
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Canton de Vaud
Swiss University